Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors

NCT05701709 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

395

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Solid Tumors

Interventions

DRUG: SHR-A2102

Sponsor

Shanghai Hengrui Pharmaceutical Co., Ltd.